The research of Nabeel Aslam, M.D., is focused on the diagnosis and treatment of glomerulonephritis: a group of diseases that cause inflammation and damage to the glomeruli. Dr. Aslam has several ongoing research trials to treat glomerulonephritis in partnership with the Mayo Nephrology Collaborative Group.
- Idiopathic membranous nephropathy. Dr. Aslam is working to determine the role of rituximab in the treatment of idiopathic membranous nephropathy. As co-investigator for Mayo Clinic's Membranous Nephropathy Trial of Rituximab (MENTOR) trial, Dr. Aslam is exploring the utility of anti-PLA2R antibodies in the diagnosis and management of idiopathic membranous nephropathy.
- IgA nephropathy. Dr. Aslam is studying the use of corticotropin (H.P. Acthar Gel) in the management of patients who have IgA nephropathy with proteinuria.
- Plasma cell disorders and kidney diseases. Dr. Aslam collaborates with Mayo Clinic's Division of Hematology to study the involvement of kidneys in patients with plasma cell disorders and to explore various therapeutic options.
Significance to patient care
Glomerulonephritis disorders are the third most common type of kidney disease. It is thought that the condition is often caused by immune system dysfunction, but in many cases the exact cause is unknown.
Currently there is no standard treatment for glomerulonephritis and therapeutic options are limited. Dr. Aslam hopes to find the best therapeutic agents to treat patients with glomerulonephritis.